Effect of DNA damage response mutations on prostate cancer prognosis: a systematic review

Stephanie L. Swift; Shona H. Lang; Heath White; Kate Misso; Jos Kleijnen; Ruben G. W. Quek

doi:10.2217/fon-2019-0298

Effect of DNA damage response mutations on prostate cancer prognosis: a systematic review

Stephanie L. Swift^*, Shona H. Lang, Heath White, Kate Misso, Jos Kleijnen, Ruben G. W. Quek

^*Corresponding author for this work

Research output: Contribution to journal › (Systematic) Review article › peer-review

7 Citations (Web of Science)

Abstract

The prognosis of men with prostate cancer (PC) with mutations in DNA damage response (DDR) genes undergoing different treatments is unclear. This systematic review compared clinical outcomes in PC patients with DDR mutations (DDR+) versus no mutations (DDR-). 14 resources plus gray literature were searched for studies in PC and subgroups (castration-resistant PC, metastatic PC and metastatic castration-resistant PC) by DDR gene (ATM, ATR, BRCA1, BRCA2, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, RAD51C) mutation status. From 11,648 records, 26 studies were included. For mCRPC, six studies reported comparative efficacy for key outcomes. Improvements in several clinical outcomes were observed for DDR+ (vs DDR-) after PARP inhibitor therapy or immunotherapy. DDR+ PC patients may have improved outcomes depending on the treatment they undergo.

Original language	English
Pages (from-to)	3283-3302
Number of pages	20
Journal	Future Oncology
Volume	15
Issue number	28
DOIs	https://doi.org/10.2217/fon-2019-0298
Publication status	Published - Oct 2019

Keywords

ATM
BRCA1
BRCA2
DDR
DNA damage response
genes
mutation
outcome
prostate cancer
therapy
BRCA MUTATIONS
REPAIR
RADIATION
ASSOCIATION
VARIANTS
TOXICITY
THERAPY
RISK
MEN
POLYMORPHISMS

Access to Document

10.2217/fon-2019-0298

Cite this

@article{42ba74a75bcf4423bf4afe2302f629f7,

title = "Effect of DNA damage response mutations on prostate cancer prognosis: a systematic review",

abstract = "The prognosis of men with prostate cancer (PC) with mutations in DNA damage response (DDR) genes undergoing different treatments is unclear. This systematic review compared clinical outcomes in PC patients with DDR mutations (DDR+) versus no mutations (DDR-). 14 resources plus gray literature were searched for studies in PC and subgroups (castration-resistant PC, metastatic PC and metastatic castration-resistant PC) by DDR gene (ATM, ATR, BRCA1, BRCA2, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, RAD51C) mutation status. From 11,648 records, 26 studies were included. For mCRPC, six studies reported comparative efficacy for key outcomes. Improvements in several clinical outcomes were observed for DDR+ (vs DDR-) after PARP inhibitor therapy or immunotherapy. DDR+ PC patients may have improved outcomes depending on the treatment they undergo.",

keywords = "ATM, BRCA1, BRCA2, DDR, DNA damage response, genes, mutation, outcome, prostate cancer, therapy, BRCA MUTATIONS, REPAIR, RADIATION, ASSOCIATION, VARIANTS, TOXICITY, THERAPY, RISK, MEN, POLYMORPHISMS",

author = "Swift, {Stephanie L.} and Lang, {Shona H.} and Heath White and Kate Misso and Jos Kleijnen and Quek, {Ruben G. W.}",

year = "2019",

month = oct,

doi = "10.2217/fon-2019-0298",

language = "English",

volume = "15",

pages = "3283--3302",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Future Medicine Ltd.",

number = "28",

}

TY - JOUR

T1 - Effect of DNA damage response mutations on prostate cancer prognosis

T2 - a systematic review

AU - Swift, Stephanie L.

AU - Lang, Shona H.

AU - White, Heath

AU - Misso, Kate

AU - Kleijnen, Jos

AU - Quek, Ruben G. W.

PY - 2019/10

Y1 - 2019/10

N2 - The prognosis of men with prostate cancer (PC) with mutations in DNA damage response (DDR) genes undergoing different treatments is unclear. This systematic review compared clinical outcomes in PC patients with DDR mutations (DDR+) versus no mutations (DDR-). 14 resources plus gray literature were searched for studies in PC and subgroups (castration-resistant PC, metastatic PC and metastatic castration-resistant PC) by DDR gene (ATM, ATR, BRCA1, BRCA2, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, RAD51C) mutation status. From 11,648 records, 26 studies were included. For mCRPC, six studies reported comparative efficacy for key outcomes. Improvements in several clinical outcomes were observed for DDR+ (vs DDR-) after PARP inhibitor therapy or immunotherapy. DDR+ PC patients may have improved outcomes depending on the treatment they undergo.

AB - The prognosis of men with prostate cancer (PC) with mutations in DNA damage response (DDR) genes undergoing different treatments is unclear. This systematic review compared clinical outcomes in PC patients with DDR mutations (DDR+) versus no mutations (DDR-). 14 resources plus gray literature were searched for studies in PC and subgroups (castration-resistant PC, metastatic PC and metastatic castration-resistant PC) by DDR gene (ATM, ATR, BRCA1, BRCA2, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, RAD51C) mutation status. From 11,648 records, 26 studies were included. For mCRPC, six studies reported comparative efficacy for key outcomes. Improvements in several clinical outcomes were observed for DDR+ (vs DDR-) after PARP inhibitor therapy or immunotherapy. DDR+ PC patients may have improved outcomes depending on the treatment they undergo.

KW - ATM

KW - BRCA1

KW - BRCA2

KW - DDR

KW - DNA damage response

KW - genes

KW - mutation

KW - outcome

KW - prostate cancer

KW - therapy

KW - BRCA MUTATIONS

KW - REPAIR

KW - RADIATION

KW - ASSOCIATION

KW - VARIANTS

KW - TOXICITY

KW - THERAPY

KW - RISK

KW - MEN

KW - POLYMORPHISMS

U2 - 10.2217/fon-2019-0298

DO - 10.2217/fon-2019-0298

M3 - (Systematic) Review article

C2 - 31535940

VL - 15

SP - 3283

EP - 3302

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 28

ER -